Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼Ò¾Æ¿¡¼­ ¼Ò¿ë·® ¾Æ½ºÇǸ°ÀÇ Àå±â°£ »ç¿ë¿¡ ÀÇÇÑ À§¡¤Àå°ü ÃâÇ÷ À§Ç輺¿¡ ´ëÇÑ ¿¬±¸ Risk of Gastrointestinal Bleeding Associated with Use of Low-dose Aspirin in Korean Children

´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸÁö 2003³â 6±Ç 1È£ p.10 ~ 16
¹è¼±È¯, ¼Õµ¿¿ì, ¹Ú°æÈñ,
¼Ò¼Ó »ó¼¼Á¤º¸
¹è¼±È¯ ( Bae Sun-Hwan ) 
À»Áö´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

¼Õµ¿¿ì ( Son Dong-Woo ) 
º½ºûº´¿ø ¼Ò¾Æ°ú
¹Ú°æÈñ ( Park Kyung-Hee ) 
¼¼È­¼Ò¾Æ°ú

Abstract

¸ñ Àû: ¾Æ½ºÇǸ°À» ºñ·ÔÇÑ NSAIDÀÇ »ç¿ëÀÌ À§Àå°ü ÃâÇ÷ µî ¿©·¯ °¡Áö À§¡¤Àå°üÇÕº´ÁõÀÇ À§Ç輺À» Áõ°¡½ÃÅ°´Â °ÍÀº ÀÌ¹Ì Àß ¾Ë·ÁÁø »ç½ÇÀÌ´Ù. ¼Ò¾Æ¿¡¼­ ¿°Áõ¼º ÁúȯÀ̳ª ÇØ¿­Á¦·Î »ç¿ëÇÏ´Â Åë»ó¿ë·®ÀÇ ¾Æ½ºÇǸ°º¸´Ù 10ºÐÀÇ 1Á¤µµÀÇ ¼Ò¿ë·®À» »ç¿ëÇÏ´Â °æ¿ì°¡ Á¾Á¾ ÀÖÀ¸³ª, ÀÌ¿Í ¿¬°üµÈ À§¡¤Àå°ü ÃâÇ÷ÀÇ À§Ç輺¿¡ ´ëÇÑ ¿¬±¸´Â °ÅÀÇ ¾ø´Ù. ÀÌ¿¡ ÀúÀÚµéÀº Kawasakiº´À¸·Î ¾Æ½ºÇǸ°À» »ç¿ëÇÑ ¼Ò¾ÆµéÀ» ´ë»óÀ¸·Î ¼Ò¿ë·® ¾Æ½ºÇǸ°ÀÇ Àå±âÀû »ç¿ë¿¡ ÀÇÇÑ À§¡¤Àå°ü ÃâÇ÷ÀÇ À§Ç輺À» Æò°¡ÇÏ°íÀÚ ÇÏ¿´´Ù.

¹æ ¹ý: 1995³âºÎÅÍ 2001³â 5¿ù±îÁö À»Áöº´¿ø ¼Ò¾Æ°ú¿¡¼­ Kawasakiº´À¸·Î Áø´Ü¹Þ°í ÀÔ¿ø Ä¡·áÇÏ¿´´ø ¼Ò¾Æ°¡¿îµ¥, ÀÓ»ó ±â·ÏÀ» È®ÀÎÇÏ°í º¸È£ÀÚ¿Í ÀüÈ­ÅëÈ­¸¦ ÇÏ¿© À§Àå°ü ÃâÇ÷ ¿©ºÎ¸¦ È®ÀÎÇÒ ¼ö ÀÖ¾ú´ø ¼Ò¾Æ 100¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. À§¡¤Àå°ü ÃâÇ÷ ¿©ºÎ´Â ȯ¾ÆÀÇ ÀÓ»ó ±â·ÏÀ» È®ÀÎÇÏ°í, º¸È£ÀÚ¿Í Á÷Á¢ ÀüÈ­ ÀÎÅͺ並 ÇÏ¿© ¼Ò¿ë·® ¾Æ½ºÇǸ° Åõ¿© ½Ã À°¾ÈÀû ÅäÇ÷, Ç÷º¯ÀÇ À¯¹«¸¦ ¹°¾î¼­ È®ÀÎÇÏ¿´´Ù.

°á °ú: ¸ðµÎ 100¸íÀÇ È¯¾Æ°¡ ¿¬±¸ ´ë»ó¿¡ Æ÷ÇԵǾúÀ¸¸ç, ³²¾Æ 63¸í, ¿©¾Æ 37¸íÀ¸·Î À̵éÀÌ ¾Æ½ºÇǸ° Åõ¾àÀ» ½ÃÀÛÇÒ ¶§ ¿¬·ÉÀº 4~118°³¿ùÀ̾úÀ¸¸ç, ¾à 75%ÀÇ È¯¾Æ°¡ 3¼¼ ¹Ì¸¸À̾ú´Ù. ¾Æ½ºÇǸ° Åõ¾à ±â°£Àº 0.5~17°³¿ù·Î ³ªÅ¸³µÀ¸¸ç, ¾à 70%ÀÇ È¯¾Æ°¡ 2~3°³¿ù °£ÀÇ Åõ¾àÀ» ½ÃÇàÇÏ¿´´Ù. ÇÑ ¸íÀÇ È¯¾Æ¿¡¼­ À°¾ÈÀû Ç÷º¯ÀÌ ¹ß»ýÇÏ¿´´Âµ¥, ȯ¾Æ´Â Åõ¾à ´ç½Ã 18°³¿ùµÈ ¿©¾Æ·Î Åõ¾à 1°³¿ù°æ ÇÏ·ç Çѹø ¾¿ ¾à 1ÁÖÀÏ°£ À°¾ÈÀû Ç÷º¯À» º¸¾ÒÀ¸³ª, º¹ÅëÀ̳ª ´Ù¸¥ Áõ»óÀº µ¿¹ÝµÇÁö ¾Ê¾Ò´Ù. Ç÷º¯Àº ¾¾¸ÞƼµòÀ» ¾à 1ÁÖÀÏ°£ »ç¿ëÇÑ ÈÄ È£ÀüµÇ¾úÀ¸¸ç, ÀÌÈÄ ¾¾¸ÞƼµòÀ» »ç¿ëÇÏÁö ¾ÊÀ¸¸ç, ¾Æ½ºÇǸ° Åõ¾àÀ» ¾à 3°³¿ù °¡·® ´õ Áö¼ÓÇÏ¿´À¸³ª ´õ ÀÌ»óÀÇ ÃâÇ÷Àº ¾ø¾ú´Ù. 100¸íÀÇ È¯¾Æ°¡ ÃÑ 341.5°³¿ù µ¿¾È ¾Æ½ºÇǸ°À» Åõ¿©ÇÏ¿´À¸¸ç, ÀÌ °¡¿îµ¥ ÇÑ ¸í¸¸ÀÌ À°¾ÈÀû ÀåÃâÇ÷À» º¸¿©, À̸¦ 100¸íÀÇ È¯¾Æ°¡ Àϳ⵿¾È ¼Ò¿ë·® ¾Æ½ºÇǸ°À» ¸ÔÀº °ÍÀ¸·Î ȯ»êÇϸé 3.5ȸ/100¸í/1³âÀÇ ºñÀ²·Î ÀåÃâÇ÷ÀÌ ¹ß»ýÇÏ´Â °ÍÀ» ÀǹÌÇÏ°Ô µÈ´Ù.

°á ·Ð: ¼Ò¾Æ¿¡¼­ ¼Ò¿ë·® ¾Æ½ºÇǸ°ÀÇ Àå±âÀû »ç¿ëÀº ¾ÈÀüÇϳª, À§¡¤Àå°ü ÃâÇ÷ÀÇ À§Ç輺À» ³ôÀÏ ¼ö ÀÖÀ¸¹Ç·Î ÇØ´ç ȯ¾Æ¿¡ ´ëÇÑ ¼¼½ÉÇÑ ÃßÀû°üÂûÀÌ ÇÊ¿äÇϸç, À§¡¤Àå°ü ÃâÇ÷ÀÇ À§Ç輺À» °¨¼Ò½ÃÄÑÁÖ±â À§ÇÑ ´Ù¾çÇÑ ³ë·ÂÀÌ º´ÇàµÇ¾î¾ß ÇÒ °ÍÀÌ´Ù.

PURPOSE: To evaluate the risk of gastrointestinal bleeding associated with use of low-dose aspirin in children.

METHODS: Among about 250 children who received low-dose aspirin (5 mg/kg/day) under the diagnosis of Kawasaki disease, from March 1995 to May 2001, at Eul-Ji general hospital, 100 children were enrolled in this study. We reviewed the medical records and interviewed the children¡¯s parents over the phone to confirm the existence of gross gastrointestinal bleeding.

RESULTS: The age of the children at the beginning of medication ranged 4~118 months. About 75% of them was younger than 3 years old. The duration of medication ranged 0.5~17 months. About 70% of the children took the medicine for 2~3 months. Only 1 child (1%) had hematochezia during medication without any accompanying gastrointestinal symptom, and cimetidine for 1 week had cleared up the bleeding. The total duration of medication of 100 children was 341.5 months, and only 1 child had gastrointestinal bleeding. This translates into a rate of clinically significant gastrointestinal bleeding of 3.5 episodes/100 children/year.

CONCLUSION: The long-term use of low-dose aspirin is safe, but, is associated with the risk of gastrointestinal bleeding in children. Careful follow-up and efforts to reduce the risk of gastrointestinal bleeding are necessary during long-term low-dose aspirin therapy in children.

Å°¿öµå

Low dose aspirin;Gastrointestinal bleeding;Children

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS